Q-omics provides the consensus-scored KASH5 profile across patient tissues and cancer cell-line models. KASH5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KASH5 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, KASH5 RNA expression shows 13,220 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where KASH5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KASH5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KASH5 survival associations across molecular data types. KASH5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KASH5 RNA expression–survival associations across cancer types. High KASH5 expression shows unfavorable associations in KIRP, ACC, KIRC, COAD and CHOL, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KASH5 RNA expression.
This table summarizes KASH5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for KASH5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KASH5 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRP, HNSC, THCA and LIHC. The KIRP box plot shows higher KASH5 RNA expression in tumor versus normal tissue (log2 FC = +0.290, t-test p = .002).
This table shows molecular features associated with KASH5 in patient tissues and cancer cell lines. In patient samples, KASH5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KASH5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
